Detection of Ovarian Cancer Using Biomarkers
Author Information
Author(s): Gregory E Rice, Tracey A Edgell, Dominic J Autelitano
Primary Institution: HealthLinx Ltd
Hypothesis
Can midkine and anterior gradient 2 improve the detection of ovarian cancer when used in a multimarker panel?
Conclusion
The study confirms that midkine and anterior gradient 2 are useful biomarkers for ovarian cancer and improve the diagnostic utility of CA125 when used together.
Supporting Evidence
- Plasma concentrations of midkine and AGR2 were significantly higher in women with ovarian cancer compared to healthy controls.
- The multi-analyte panel showed a sensitivity of 95.2% and specificity of 97.7%.
- CA125 alone had a sensitivity of 87.0% and specificity of 94.6%.
Takeaway
This study found that two proteins in the blood can help doctors find ovarian cancer earlier, which is really important for better treatment.
Methodology
The study used a retrospective, case-control design comparing plasma concentrations of midkine, AGR2, and CA125 in women with and without ovarian cancer.
Potential Biases
Potential bias due to the retrospective design and selection of participants.
Limitations
The study did not include stage IV tumors and was limited to a specific cohort of women.
Participant Demographics
Median age of controls was 52 years (32-69), and cases were 61 years (24-69); 46 cases of ovarian cancer and 61 controls.
Statistical Information
P-Value
p < 0.001
Statistical Significance
p < 0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website